FIELD: medicine, pharmaceutics.
SUBSTANCE: invention refers to medicine, pharmacology and biology and concerns application of Trecresan as an agent to decrease cholesterol esterase activity.
EFFECT: invention allows extending the range of agents used to decrease cholesterol esterase activity.
4 tbl, 2 ex
| Title | Year | Author | Number |
|---|---|---|---|
| AGENT INTENSIFYING THROMBOCYTE ACID LYPASE ACTIVITY | 2010 |
|
RU2429833C1 |
| AGENT MODULATING ACID PHOSPHOLIPASE A1 ACTIVITY | 2010 |
|
RU2445087C1 |
| SUBSTANCE REDUCING CHOLESTEROL ESTERASE ACTIVITY | 2014 |
|
RU2540518C1 |
| USING PROTATRAN 4-CHLOR-2-METHYLPHENOXYACETATE (CHLORCRESACIN) FOR ARREST OF CHOLESTEROLESTERASE ACTIVITY | 2014 |
|
RU2563831C1 |
| TRECRESAN APPLICATION FOR TREATING PATIENTS SUFFERING ARTERIAL HYPERTENSION AND OBESITY | 2010 |
|
RU2429832C1 |
| USING COMPLEX OF TRIS-(2-HYDROXYETHYL)AMINE AND BIS-(2-METHYLPHENOXY-ACETATE) ZINC (ZINCATRAN) FOR REDUCING TOTAL ACTIVITY OF ACIDIC PHOSPHOLIPASE A1 | 2014 |
|
RU2545888C1 |
| METHOD FOR CORRECTING ATHEROGENESIS EXPERIMENTALLY USING 1-HYDROXYGERMATRANE | 2020 |
|
RU2741229C1 |
| 1-HYDROXYGERMATRANE USAGE FOR INHIBITING THE DEVELOPMENT OF ATHEROSCLEROSIS IN THE EXPERIMENT | 2020 |
|
RU2742972C1 |
| USING COMPLEX OF TRIS-(2-HYDROXYETHYL)AMINE AND ZINC BIS-(2-METHYLPHENOXYACETATE) (CINKATRAN) AS AGENT SUPPRESSING TOTAL ACTIVITY OF BASIC (ALKALINE) MONONUCLEAR PHOSPHOLIPASE A2 | 2014 |
|
RU2546537C1 |
| AGENT FOR TOTAL TRYPTOPHANYL-tRNS-SYNTHETASE ACTIVATION | 2009 |
|
RU2407526C1 |
